Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites - PubMed (original) (raw)
Review
doi: 10.1039/c0fo00132e. Epub 2010 Nov 17.
Affiliations
- PMID: 21776473
- DOI: 10.1039/c0fo00132e
Review
Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites
Maria Monagas et al. Food Funct. 2010 Dec.
Abstract
Flavan-3-ols, occurring in monomeric, as well as in oligomeric and polymeric forms (also known as condensed tannins or proanthocyanidins), are among the most abundant and bioactive dietary polyphenols, but their in vivo health effects in humans may be limited because of their recognition as xenobiotics. Bioavailability of flavan-3-ols is largely influenced by their degree of polymerization; while monomers are readily absorbed in the small intestine, oligomers and polymers need to be biotransformed by the colonic microbiota before absorption. Therefore, phenolic metabolites, rather than the original high molecular weight compounds found in foods, may be responsible for the health effects derived from flavan-3-ol consumption. Flavan-3-ol phenolic metabolites differ in structure, amount and excretion site. Phase II or tissular metabolites derived from the small intestine and hepatic metabolism are presented as conjugated derivatives (glucuronic acid or sulfate esters, methyl ether, or their combined forms) of monomeric flavan-3-ols and are preferentially eliminated in the bile, whereas microbial metabolites are rather simple conjugated lactones and phenolic acids that are largely excreted in urine. Although the colon is seen as an important organ for the metabolism of flavan-3-ols, the microbial catabolic pathways of these compounds are still under consideration, partly due to the lack of identification of bacteria with such capacity. Studies performed with synthesized or isolated phase II conjugated metabolites have revealed that they could have an effect beyond their antioxidant properties, by interacting with signalling pathways implicated in important processes involved in the development of diseases, among other bioactivities. However, the biological properties of microbe-derived metabolites in their actual conjugated forms remain largely unknown. Currently, there is an increasing interest in their effects on intestinal infections, inflammatory intestinal diseases and overall gut health. The present review will give an insight into the metabolism and microbial biotransformation of flavan-3-ols, including tentative catabolic pathways and aspects related to the identification of bacteria with the ability to catabolize these kinds of polyphenols. Also, the in vitro bioactivities of phase II and microbial phenolic metabolites will be covered in detail.
Similar articles
- Comparative biokinetics and metabolism of pure monomeric, dimeric, and polymeric flavan-3-ols: a randomized cross-over study in humans.
Wiese S, Esatbeyoglu T, Winterhalter P, Kruse HP, Winkler S, Bub A, Kulling SE. Wiese S, et al. Mol Nutr Food Res. 2015 Apr;59(4):610-21. doi: 10.1002/mnfr.201400422. Epub 2015 Feb 18. Mol Nutr Food Res. 2015. PMID: 25546356 Clinical Trial. - Influence of formulation and processing on absorption and metabolism of flavan-3-ols from tea and cocoa.
Neilson AP, Ferruzzi MG. Neilson AP, et al. Annu Rev Food Sci Technol. 2011;2:125-51. doi: 10.1146/annurev-food-022510-133725. Annu Rev Food Sci Technol. 2011. PMID: 22129378 Review. - Updated bioavailability and 48 h excretion profile of flavan-3-ols from green tea in humans.
Calani L, Del Rio D, Luisa Callegari M, Morelli L, Brighenti F. Calani L, et al. Int J Food Sci Nutr. 2012 Aug;63(5):513-21. doi: 10.3109/09637486.2011.640311. Epub 2011 Dec 2. Int J Food Sci Nutr. 2012. PMID: 22133145 - Phenyl-γ-valerolactones and phenylvaleric acids, the main colonic metabolites of flavan-3-ols: synthesis, analysis, bioavailability, and bioactivity.
Mena P, Bresciani L, Brindani N, Ludwig IA, Pereira-Caro G, Angelino D, Llorach R, Calani L, Brighenti F, Clifford MN, Gill CIR, Crozier A, Curti C, Del Rio D. Mena P, et al. Nat Prod Rep. 2019 May 22;36(5):714-752. doi: 10.1039/c8np00062j. Nat Prod Rep. 2019. PMID: 30468210 Review. - In vitro fermentation of grape seed flavan-3-ol fractions by human faecal microbiota: changes in microbial groups and phenolic metabolites.
Cueva C, Sánchez-Patán F, Monagas M, Walton GE, Gibson GR, Martín-Álvarez PJ, Bartolomé B, Moreno-Arribas MV. Cueva C, et al. FEMS Microbiol Ecol. 2013 Mar;83(3):792-805. doi: 10.1111/1574-6941.12037. Epub 2012 Nov 27. FEMS Microbiol Ecol. 2013. PMID: 23121387
Cited by
- Study on biotransformation and absorption of genistin based on fecal microbiota and Caco-2 cell.
Li Z, Wang Y, Wang Z, Wu D, Zhao Y, Gong X, Jiang Q, Xia C. Li Z, et al. Front Pharmacol. 2024 Oct 9;15:1437020. doi: 10.3389/fphar.2024.1437020. eCollection 2024. Front Pharmacol. 2024. PMID: 39444613 Free PMC article. - Research progress on the regulatory and pharmacological mechanism of chemical components of Dendrobium.
Wei X, Wang D, Xu Z, Liu J, Zhu Q, Chen Q, Tang H, Xu W. Wei X, et al. Heliyon. 2024 Sep 7;10(18):e37541. doi: 10.1016/j.heliyon.2024.e37541. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39328574 Free PMC article. Review. - Flavan-3-ols and Vascular Health: Clinical Evidence and Mechanisms of Action.
Godos J, Romano GL, Laudani S, Gozzo L, Guerrera I, Dominguez Azpíroz I, Martínez Diaz R, Quiles JL, Battino M, Drago F, Giampieri F, Galvano F, Grosso G. Godos J, et al. Nutrients. 2024 Jul 30;16(15):2471. doi: 10.3390/nu16152471. Nutrients. 2024. PMID: 39125353 Free PMC article. Review. - Review of the pharmacokinetics of French maritime pine bark extract (Pycnogenol®) in humans.
Bayer J, Högger P. Bayer J, et al. Front Nutr. 2024 May 2;11:1389422. doi: 10.3389/fnut.2024.1389422. eCollection 2024. Front Nutr. 2024. PMID: 38757126 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources